Levothyroxine Potency Standards To Be Addressed By FDA Advisory Committees
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is focusing on potential “clinically significant concerns” and will address intraproduct issues before moving to questions of bioequivalence.
You may also be interested in...
FDA Solicits Bids For Levothyroxine Stability Testing
Some manufacturers have been unable to demonstrate that their products have a two-year shelf life, the agency said.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.